These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39192830)

  • 21. Similar Pharmacokinetics of the Adalimumab (Humira
    Ramael S; Van Hoorick B; Tiessen R; van Iersel T; Moschetti V; Lang B; Sonderegger I; Wiebe S; Liedert B; Jayadeva G
    Rheumatol Ther; 2018 Dec; 5(2):403-421. PubMed ID: 29959660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient preference after switching guselkumab from prefilled syringe to an autoinjection pen in psoriasis and psoriatic arthritis patients.
    Borrás-Blasco J; García RA; Cornejo-Uixeda S; Matellanes-Palacios M; Casterá-Melchor E
    Farm Hosp; 2024 Jul; ():. PubMed ID: 39069450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design Development of the SMARTCLIC
    Berman K; Moss S; Holden-Theunissen B; Satou N; Okada K; Latymer M; Antalfy A
    Adv Ther; 2023 Jul; 40(7):3070-3086. PubMed ID: 37199860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Usability and Acceptance of a New Autoinjector Intended for Methotrexate Subcutaneous Self-Administration in the Management of Rheumatoid Arthritis.
    Hudry C; Lebrun A; Moura B; Zinovieva E; Backers O; Herman-Demars H
    Rheumatol Ther; 2017 Jun; 4(1):183-194. PubMed ID: 28243967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial.
    Kivitz A; Cohen S; Dowd JE; Edwards W; Thakker S; Wellborne FR; Renz CL; Segurado OG
    Clin Ther; 2006 Oct; 28(10):1619-29. PubMed ID: 17157117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis.
    Pachon JA; Kivitz AJ; Heuer KU; Pichlmeier U
    SAGE Open Med; 2014; 2():2050312114564241. PubMed ID: 26770759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
    Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W
    Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program.
    Karlsdottir K; Gunnarsdottir AI; Grondal G; Love TJ; Stefansdottir E; Davidsdottir LG; Thorleifsdottir RH; Gudbjornsson B
    Front Med (Lausanne); 2022; 9():799494. PubMed ID: 35155495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector.
    Müller-Ladner U; Edwards CJ; Erkens A
    Patient Prefer Adherence; 2024; 18():579-590. PubMed ID: 38463400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17.
    Viapiana O; Lee S; Yoon S; Fautrel B
    Clin Drug Investig; 2022 Feb; 42(2):103-112. PubMed ID: 35025072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE
    Cohen S; Klimiuk PA; Krahnke T; Assudani D
    Expert Opin Drug Deliv; 2018 Jun; 15(6):545-548. PubMed ID: 29764238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
    Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
    J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis.
    Little RD; Chu IE; van der Zanden EP; Flanagan E; Bell SJ; Gibson PR; Sparrow MP; Shelton E; Connor SJ; Roblin X; Ward MG
    J Crohns Colitis; 2019 Dec; 13(12):1527-1536. PubMed ID: 31094417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
    Shin D; Lee Y; Jeong D; Ellis-Pegler R
    Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study.
    Welcker JT; Nawroth F; Bilger W
    Reprod Biol Endocrinol; 2010 Sep; 8():111. PubMed ID: 20843323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantifying Patient Capabilities and Setting the Stage for Future Development: Insights from a Sensor-Augmented Simulated Use Study with Pen Injectors.
    Lange J; Schneider AE; Jordi C
    Med Devices (Auckl); 2024; 17():271-283. PubMed ID: 39099757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM
    Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
    Wang Y; Gao Z; Liu Z; Liu G; Qu X; Chen J; Ren X; Xu Z; Yang H
    Expert Opin Biol Ther; 2022 Feb; 22(2):225-234. PubMed ID: 34134579
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.